Connect Biopharma Holdings Limited Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Connect Biopharma Holdings Limited (CNTB) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-12
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$1.00K.
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$4.00K.
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $6.00K, a 500.00% increase year-over-year.
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was -$11.00K.
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $2.00K, a 83.33% decline from fiscal 2024.
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $12.00K, a 96.61% decline from fiscal 2023.
- Connect Biopharma Holdings Limited debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $354.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K 10-Q · filed 2026-08-12 | -$5.00K 10-Q · filed 2026-08-12 | $1.00K derived: sum of 3 quarters · filed 2026-08-12 | -$10.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$4.00K 10-Q · filed 2026-05-12 | $2.00K derived: sum of 2 quarters · filed 2026-05-12 | -$9.00K derived: sum of 3 quarters · filed 2026-05-12 | -$15.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.00K derived: sum of 2 quarters · filed 2026-03-31 | -$11.00K derived: sum of 3 quarters · filed 2026-08-12 | $2.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$11.00K 10-Q · filed 2025-11-12 | -$17.00K derived: sum of 2 quarters · filed 2026-08-12 | -$4.00K 10-Q · filed 2025-11-12 | -$17.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$6.00K 10-Q · filed 2026-08-12 | -$7.00K 10-Q · filed 2026-08-12 | -$6.00K derived: sum of 3 quarters · filed 2026-08-12 | -$6.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$1.00K 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $2.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.00K derived: sum of 2 quarters · filed 2026-03-31 | $3.00K derived: sum of 3 quarters · filed 2026-03-31 | $12.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $2.00K derived: sum of 2 quarters · filed 2025-11-12 | $11.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $2.00K 10-Q · filed 2025-08-13 | $11.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $9.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $354.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |